Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Cancer Clinical Trial

Official title:
Phase II Study of Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

Status Terminated

Clinical Trial Summary

This is a prospective, randomized phase II trial. Patients diagnosed with borderline resectable pancreatic adenocarcinoma will be randomly assigned to one of two treatment arms, either mFOLFIRINOX or gemcitabine and nab-paclitaxel. After three cycles of treatment in the gemcitabine/nab-paclitaxel arm and 6 cycles in the mFOLFIRINOX arm, patients will be restaged with CT scans and if they remain borderline resectable or have improvement of their disease They will then proceed to SBRT followed by surgical resection.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Borderline Resectable Pancreatic Cancer
Pancreatic Neoplasms

Clinical Trial Details

NCT number	NCT02241551
Study type	Interventional
Source	University of Pittsburgh
Contact
Status	Terminated
Phase	Phase 2
Start date	December 2014
Completion date	March 3, 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04617821` - AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer	Phase 3
Suspended	`NCT04090463` - IORT on Borderline Resectable Pancreatic Cancer	Phase 2
Terminated	`NCT04698915` - Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer	Phase 2
Recruiting	`NCT03850769` - Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer	Phase 2
Not yet recruiting	`NCT03443921` - Divestment for Artery-involved Pancreatic Cancer	N/A
Recruiting	`NCT06345300` - NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study	Phase 2
Not yet recruiting	`NCT06384560` - Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5)	Phase 1/Phase 2
Active, not recruiting	`NCT02717091` - Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer	Phase 2
Not yet recruiting	`NCT06387810` - Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer	Phase 2
Recruiting	`NCT04855331` - Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC	N/A